Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2234353 | 0.82 | LMNA (0.55) | LMNATLR8ALDH1A1GAANR1I2 | |
| SCHEMBL13851094 | 0.77 | LMNA (0.56) | LMNATLR8ALDH1A1GAANR1I2 | |
| SCHEMBL30669887 | 0.77 | LMNA (0.33) | LMNAIKBKBMAP3K14CYP1A2 | |
| SCHEMBL8081435 | 0.77 | LMNA (0.33) | LMNAIKBKBMAP3K14CYP1A2 | |
| Bromide SCHEMBL8547428 | 0.75 | LMNA (0.61) | LMNATLR8ALDH1A1GAANR1I2 | |
| SCHEMBL29464296 | 0.75 | LMNA (0.37) | LMNA | |
| SCHEMBL30420099 | 0.75 | ALDH1A1 (0.40) | LMNATLR8ALDH1A1GAAKDM4E | |
| SCHEMBL14967319 | 0.75 | LMNA (0.37) | LMNAHPGD | |
| SCHEMBL22055454 | 0.75 | LMNA (0.37) | LMNA | |
| SCHEMBL12368143 | 0.75 | ALDH1A1 (0.40) | LMNATLR8ALDH1A1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2019-05-16 | — | — | US | claimed |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2017-02-09 | — | — | US | claimed |
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2015-01-08 | — | — | US | claimed |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CACAO BIO-TECHNOLOGIES, LLC (US) | 2011-09-08 | — | — | US | claimed |
| US-6962695-B1 | Modification of interferon alpha production | BIONATIVE AB (SE) | 2005-11-08 | — | — | US | claimed |
| EP-1141012-B1 | MODIFICATION OF INTERFERON ALPHA PRODUCTION | VIRANATIVE AB (SE) | 2005-06-29 | — | — | EP | claimed |
| US-6846525-B2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 2005-01-25 | — | — | US | claimed |
| US-20040202825-A1 | RECORDING SHEETS CONTAINING PURINE, PYRIMIDINE, BENZIMIDAZOLE, IMIDAZOLIDINE, URAZOLE, PYRAZOLE, TRIAZOLE, BENZOTRIAZOLE, TETRAZOLE, AND PYRAZINE COMPOUNDS | XEROX CORPORATION | 2004-10-14 | — | — | US | claimed |
| EP-1141012-A1 | MODIFICATION OF INTERFERON ALPHA PRODUCTION | Bionative AB (SE) | 2001-10-10 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| WO-2000039163-A1 | MODIFICATION OF INTERFERON ALPHA PRODUCTION | BIONATIVE AB (SE) | 2000-07-06 | — | — | WO | claimed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
| US-5659348-A | APPLYING TO A SUBSTRATE | XEROX CORPORATION (US) | 1997-08-19 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| US-3932617-A | AMINOHALOALKYLPYRIMIDINOLS | THE UPJOHN COMPANY (US) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011488-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | LMNA 1691/4885TLR8 127/4885ALDH1A1 1440/4885 |
| US-20170035726-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | LMNA 1691/4885TLR8 127/4885ALDH1A1 1440/4885 |
| US-20110218241-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, MGMT | LMNA 1543/4885TLR8 192/4885ALDH1A1 1234/4885 |
| US-20190142792-A1 | ANTIVIRAL EPICATECHINS, EPICATECHIN OLIGOMERS, OR THIOLATED EPICATECHINS FROM THEOBROMA CACAO FOR TREATMENT OF GENITAL WARTS | CUTA, OGG1, HAAO | LMNA 1691/4885TLR8 127/4885ALDH1A1 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.